176 related articles for article (PubMed ID: 34436829)
1. Comparison of intravenous and non-intravenous antibiotic regimens in eradication of P. aeruginosa and MRSA in cystic fibrosis.
Mursaloglu HH; Akın C; Yılmaz Yeğit C; Ergenekon AP; Suzer Uzunoglu B; Taştan G; Gökdemir Y; Erdem Eralp E; Karahasan Yağcı A; Karakoç F; Karadağ B
Pediatr Pulmonol; 2021 Dec; 56(12):3745-3751. PubMed ID: 34436829
[TBL] [Abstract][Full Text] [Related]
2. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR
Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975
[TBL] [Abstract][Full Text] [Related]
3. A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study.
Maliniak ML; Stecenko AA; McCarty NA
J Cyst Fibros; 2016 May; 15(3):350-6. PubMed ID: 26610860
[TBL] [Abstract][Full Text] [Related]
4. The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis.
Emiralioglu N; Yalcin E; Meral A; Sener B; Dogru D; Ozcelik U; Kiper N
J Clin Pharm Ther; 2016 Aug; 41(4):419-23. PubMed ID: 27311742
[TBL] [Abstract][Full Text] [Related]
5. Association between Staphylococcus aureus alone or combined with Pseudomonas aeruginosa and the clinical condition of patients with cystic fibrosis.
Hubert D; Réglier-Poupet H; Sermet-Gaudelus I; Ferroni A; Le Bourgeois M; Burgel PR; Serreau R; Dusser D; Poyart C; Coste J
J Cyst Fibros; 2013 Sep; 12(5):497-503. PubMed ID: 23291443
[TBL] [Abstract][Full Text] [Related]
6. Antibiotics and outcomes of CF pulmonary exacerbations in children infected with MRSA and Pseudomonas aeruginosa.
Cogen JD; Hall M; Faino AV; Ambroggio L; Blaschke AJ; Brogan TV; Cotter JM; Gibson RL; Grijalva CG; Hersh AL; Lipsett SC; Shah SS; Shapiro DJ; Neuman MI; Gerber JS
J Cyst Fibros; 2023 Mar; 22(2):313-319. PubMed ID: 35945130
[TBL] [Abstract][Full Text] [Related]
7. Eradication of methicillin resistant Staphylococcus aureus detected for the first time in cystic fibrosis: A single center observational study.
Kappler M; Nagel F; Feilcke M; Kröner C; Pawlita I; Naehrig S; Ripper J; Hengst M; von Both U; Forstner M; Hector A; Griese M
Pediatr Pulmonol; 2016 Oct; 51(10):1010-1019. PubMed ID: 27378061
[TBL] [Abstract][Full Text] [Related]
8. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial.
Hewer SCL; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Williamson PR;
Lancet Respir Med; 2020 Oct; 8(10):975-986. PubMed ID: 33007285
[TBL] [Abstract][Full Text] [Related]
9. Multicenter Observational Study on Factors and Outcomes Associated with Various Methicillin-Resistant Staphylococcus aureus Types in Children with Cystic Fibrosis.
Muhlebach MS; Heltshe SL; Popowitch EB; Miller MB; Thompson V; Kloster M; Ferkol T; Hoover WC; Schechter MS; Saiman L;
Ann Am Thorac Soc; 2015 Jun; 12(6):864-71. PubMed ID: 25745825
[TBL] [Abstract][Full Text] [Related]
10. The effect of Pseudomonas aeruginosa eradication regimens on chronic colonization and clinical outcomes in pediatric patients with cystic fibrosis.
Nayir Buyuksahin H; Yalçın E; Emiralioglu N; Hazırolan G; Ademhan Tural D; Ozsezen B; Sunman B; Guzelkas I; Dogru D; Ozcelik U; Kiper N
Pediatr Int; 2022 Jan; 64(1):e15249. PubMed ID: 36321341
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of a methicillin-resistant Staphylococcus aureus (MRSA) eradication protocol in pediatric cystic fibrosis (CF) patients.
Belarski E; Pettit R
Pediatr Pulmonol; 2020 Mar; 55(3):654-659. PubMed ID: 31899860
[TBL] [Abstract][Full Text] [Related]
12. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Greally P; Whitaker P; Peckham D
Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
[TBL] [Abstract][Full Text] [Related]
13. Antibiotics Enhance Prevention and Eradication Efficacy of Cathodic-Voltage-Controlled Electrical Stimulation against Titanium-Associated Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa Biofilms.
Canty MK; Hansen LA; Tobias M; Spencer S; Henry T; Luke-Marshall NR; Campagnari AA; Ehrensberger MT
mSphere; 2019 May; 4(3):. PubMed ID: 31043516
[TBL] [Abstract][Full Text] [Related]
14. Nebulized gentamicin in combination with systemic antibiotics for eradicating early Pseudomonas aeruginosa infection in children with cystic fibrosis.
Van Stormbroek B; Zampoli M; Morrow BM
Pediatr Pulmonol; 2019 Apr; 54(4):393-398. PubMed ID: 30656856
[TBL] [Abstract][Full Text] [Related]
15. Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis--the PMEP trial: study protocol for a randomized controlled trial.
Jennings MT; Boyle MP; Weaver D; Callahan KA; Dasenbrook EC
Trials; 2014 Jun; 15():223. PubMed ID: 24925006
[TBL] [Abstract][Full Text] [Related]
16. Interventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.
Lo DK; Hurley MN; Muhlebach MS; Smyth AR
Cochrane Database Syst Rev; 2013 Feb; (2):CD009650. PubMed ID: 23450608
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic Tolerance and Treatment Outcomes in Cystic Fibrosis Methicillin-Resistant Staphylococcus aureus Infections.
Lu KY; Wagner NJ; Velez AZ; Ceppe A; Conlon BP; Muhlebach MS
Microbiol Spectr; 2023 Feb; 11(1):e0406122. PubMed ID: 36519944
[TBL] [Abstract][Full Text] [Related]
18. Association of Intensity of Antipseudomonal Antibiotic Therapy With Risk of Treatment-Emergent Organisms in Children With Cystic Fibrosis and Newly Acquired Pseudomonas Aeruginosa.
Cogen JD; Onchiri FM; Hamblett NM; Gibson RL; Morgan WJ; Rosenfeld M
Clin Infect Dis; 2021 Sep; 73(6):987-993. PubMed ID: 33693586
[TBL] [Abstract][Full Text] [Related]
19. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE
J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275
[TBL] [Abstract][Full Text] [Related]
20. Impact of colonizing organism in the respiratory tract on the incidence, duration, and time between subsequent hospitalizations among patients with cystic fibrosis.
Cios K; Cohen B; Quittell LM; Liu J; Larson EL
Am J Infect Control; 2019 Jul; 47(7):750-754. PubMed ID: 30732978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
